ArticleFrontiers in endocrinology2025
Curvilinear relationship between life's crucial 9 and metabolic syndrome in U.S. adults: a cross-sectional study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic Syndrome (MetS) is closely linked to cardiovascular disease. However, no studies have examined the relationship between Life's Crucial 9 (LC9) and MetS. Our goal is to investigate the potential association between LC9 and MetS. Methods: We employed a weighted multivariate logistic regression model to evaluate the relationship between LC9, health behavior score, health factors score, and MetS. To assess the robustness of this association, we conducted sensitivity analyses. Furthermore, we utilized smooth curve fitting to investigate the potential curvilinear relationships between LC9, health behavior score, health factors score, and MetS. To pinpoint inflection points, we integrated recursive partitioning algorithms with a two-stage linear regression model. Additionally, we performed stratified analyses to explore heterogeneity across different population subgroups. Results: Our study included a total of 28,555 participants. In the regression model that accounted for all covariates, the OR for LC9 and MetS was 0.941 (0.939, 0.944), indicating a significant negative correlation between the two. Smooth curve analysis confirmed a curvilinear relationship between LC9 and MetS, with an inflection point at 70.56. The negative correlation was evident both before and after the inflection point, with a more pronounced effect after the inflection point. Subgroup analyses of Health behavior score and Health factors score, as well as stratified analyses by age, sex, and BMI, showed that all groups exhibited curvilinear relationships consistent with the overall pattern. Conclusion: The curvilinear relationship between LC9 scores and metabolic syndrome indicates that higher LC9 scores act as a protective factor against MetS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.